In this article
Global Economic Forecast of Cancer Costs (2020–2050)
Feb 2023: According to data published in JAMA Oncology, the global economic cost of cancer is projected to reach $25.2 trillion in international dollars (INT) between 2020 and 2050.
North America is projected to have the highest cost, and China is projected to have the highest cost per capita. The cancers of the trachea, bronchus, and lung are anticipated to incur the highest costs.
Researchers used a macroeconomic model to make these forecasts. Between 2020 and 2050, they projected the cost of 29 cancers in 204 countries and territories.
Economic Impact by Country and Region
The United States ($5,300 billion), China ($6,100 billion), and India ($1,400 billion) will bear the highest economic costs.
Bulgaria (1.42%), Monaco (1.33%), and Montenegro (1.0%) are the countries with the highest projected economic costs as a percentage of gross domestic product. The projected economic cost per capita is greatest in Monaco ($85,230), Ireland ($54,009), and Bermuda ($20,732)
North America is projected to have the highest economic burden from cancer as a proportion of gross domestic product, equivalent to a 0.83 percent annual tax. Europe and Central Asia (0.63%), East Asia and the Pacific (0.59%), and Sub-Saharan Africa (0.24%) follow.
Highest Cost Cancer Types
By cancer type, the highest economic cost is projected for:
Cancers of the trachea, bronchus, and lung (INT $3.9 trillion)
Colon and rectum cancer (INT $2.8 trillion)
Breast cancer (INT $2.0 trillion)
Liver cancer (INT $1.7 trillion)
Leukemia (INT $1.6 trillion)
The researchers noted that these cancers account for half of the global economic cost of cancer.
The researchers wrote, “The macroeconomic cost of cancer was found to be substantial and heterogeneously distributed across cancer types, countries, and world regions.”
Study Limitations and Disclosures
A related editorial highlighted the study’s limitations, including the absence of data for 60 countries, or 7.3% of the total population.
Disclosures: The study authors reported having no conflicts of interest. The editorial author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original references for a full list of disclosures.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.